News & Updates
Filter by Specialty:
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
26 Jul 2022
Poor lifestyle ups risk of incident psoriasis
Poor lifestyle appears to increase the risk of incident psoriasis irrespective of genetic risk, suggest the results of a recent study. Additionally, lifestyle factors have a greater relative impact than genetic risk.
Poor lifestyle ups risk of incident psoriasis
24 Jul 2022
Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.
Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
22 Jul 2022
Investigational nitric oxide gel for water warts scores high in phase III trial
A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.
